dpp-4 inhibitors and glp-1 agonists dpp-4_inhibitors [TUSOM Clinical Use of DPP-4 Inhibitors
Description
Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al

Can I switch between injectable and oral GLP-1s

Diabetes Obes Metab 24(1):94105 Zaazouee MS et al (2022) Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes

Early biosimilar pipelines now coincide with once-weekly and dual-incretin innovations, encouraging payers to re-examine cost-effectiveness thresholds and to broaden indication coverage beyond glycemic control
Cell Mol Gastroenterology Hepatology
